Improving the safety of iPSC-derived T cell therapy

Miki Ando, Shintaro Kinoshita, Yoshiki Furukawa, Jun Ando, Hiromitsu Nakauchi, Malcolm K. Brenner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies. However, for most cancers, clinical utility is limited. CTLs continuously exposed to viral or tumor antigens, with long-term expansion, may become exhausted. Exploiting fully rejuvenated iPSC-derived antigen-specific CTLs would be a powerful approach. The chapter focuses on recent progress in engineering iPSC-derived T cells for “off-the-shelf” T cell therapy and on the importance of introducing a suicide gene safeguard system into adoptive T cell therapy, including iPSC-derived T cell therapy, to protect safety in clinical trials.

Original languageEnglish (US)
Title of host publicationMolecular Players in iPSC Technology
PublisherElsevier
Pages95-115
Number of pages21
ISBN (Electronic)9780323900591
DOIs
StatePublished - Jan 1 2021

Keywords

  • Chimeric antigen receptor T cells
  • Cytotoxic T lymphocytes
  • Inducible caspase-9
  • Rejuvenated T cells
  • Suicide-gene-based safeguard system
  • T-iPSCs
  • Virus-specific CTLs
  • “Off-the-shelf” T cell therapy

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Improving the safety of iPSC-derived T cell therapy'. Together they form a unique fingerprint.

Cite this